Mewburn Ellis is pleased to announce that we have extended our residency at the BioInnovation Institute (BII) in Copenhagen for another two years — a decision that reinforces our long-standing commitment to the Danish innovation landscape.
Our continued presence at BII reflects not only our dedication to the life sciences sector, but also to the growing ecosystem of quantum technologies emerging in Denmark. From cutting-edge biotech to next-generation computing, we’re proud to support the visionaries turning bold ideas into transformative solutions.
BII, an international foundation backed by the Novo Nordisk Foundation, plays a vital role in accelerating early-stage life science start-ups. Through access to state-of-the-art lab space, business acceleration programmes, and a dynamic network of researchers and entrepreneurs, it provides a unique environment where innovation can flourish. Being part of this ecosystem allows us to deliver in-person, strategic IP guidance to the businesses that need it most.
Since first joining the BII community, we’ve worked closely with founders and research teams, helping them navigate the complexities of intellectual property — from securing foundational patents to preparing for investment and growth. This extension ensures we can continue offering tailored, practical support on the ground, as start-ups move from concept to commercialisation.
Our renewed residency reflects one simple idea: to be where innovation happens, and to help shape its future.
Image: Esben Zøllner Olesen for BioInnovation Institute.
